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Abstract
Central nervous system (CNS) relapse is a devastating complication that occurs in about 5% of diffuse large B-cell lymphoma 
(DLBCL) patients. Currently, there are no predictive biological markers. We wanted to study potential biomarkers of CNS 
tropism that play a role in adhesion, migration and/or in the regulation of inflammatory responses. The expression levels of 
ITGA10, CD44, PTEN, cadherin-11, CDH12, N-cadherin, P-cadherin, lactoferrin and E-cadherin were studied with IHC and IEM. 
GEP was performed to see whether found expressional changes are regulated at DNA/RNA level. IHC included 96 samples of 
primary CNS lymphoma (PCNSL), secondary CNS lymphoma (sCNSL) and systemic DLBCL (sDLBCL). IEM included two PCNSL, 
one sCNSL, one sDLBCL and one reactive lymph node samples. GEP was performed on two DLBCL samples, one with and 
one without CNS relapse. CNS disease was associated with enhanced expression of cytoplasmic and membranous ITGA10 
and nuclear PTEN (P < 0.0005, P = 0.002, P = 0.024, respectively). sCNSL presented decreased membranous CD44 and nuclear 
and cytoplasmic cadherin-11 expressions (P = 0.001, P = 0.006, P = 0.048, respectively). In PCNSL lactoferrin expression was 
upregulated (P < 0.0005). IEM results were mainly supportive of the IHC results. In GEP CD44, cadherin-11, lactoferrin and 
E-cadherin were under-expressed in CNS disease. Our results are in line with previous studies, where gene expressions in 
extracellular matrix and adhesion-related pathways are altered in CNS lymphoma. This study gives new information on the 
DLBCL CNS tropism. If further verified, these markers might become useful in predicting CNS relapses.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common 
lymphoma subtype, representing about 30% of all lymphomas. 
In addition to systemic disease, it can also manifest in the cen-
tral nervous system (CNS) in the form of secondary CNS involve-
ment of systemic DLBCL or as primary CNS lymphoma (PCNSL). 
The latter is a rare disease, representing 1–2% of all non-Hodg-
kin lymphomas (1).
Of systemic DLBCL patients, around 5% will have disease 
involvement in the CNS either during diagnosis, or more com-
monly, a few months afterwards (2,3). The inclusion of rituxi-
mab in the treatment has increased the effective control of 
the systemic DLBCL, but the data considering its effect on the 
risk of a CNS relapse is contradictory. Before the rituximab era, 
CNS involvement was usually seen simultaneously with refrac-
tory, widespread systemic disease (4,5). This paradigm has 
changed and currently the emergence of solitary CNS relapses 
has become an increasing problem. Patients with a CNS relapse 
have a dismal prognosis. High-dose methotrexate and cytara-
bine included in the primary treatment of systemic DLBCL seem 
to reduce the risk of a CNS relapse. However it is associated with 
considerable toxicity and the identification of patients at high 
risk of CNS relapse still remains problematic today (6,7).
Currently the patient selection for CNS prophylaxis is car-
ried out by clinical risk assessment based on the following 
clinical factors: high International Prognostic Index (IPI) score, 
advanced stage, elevated lactate dehydrogenase, age > 60 years 
and involvement of extranodal sites (such as paraspinal or para-
nasal location, testes or breast). At best, this clinical evaluation 
is able to identify a patient population with a 20% risk of CNS 
disease, thus the number needed to treat to prevent one relapse 
is high. There is also a small group of patients who will later 
develop CNS disease and fail to be detected by this clinical risk 
score. There is an unmet clinical need for biological markers 
that could be used for predicting CNS recurrence (8).
Based on our previous study and literature, we hypothe-
sized that CXCR4/CXCL12 signalling mediates the CNS homing 
of lymphoma cells and provokes an epithelial–mesenchymal 
transition (EMT)-like process (9). CXCR4/CXCL12 signalling has 
been linked to the expression and/or activity of integrins, CD44 
(a cell-surface glycoprotein), phosphatase and tensin homolog 
(PTEN), cadherin-11, N-cadherin and E-cadherin (10–14). Integrin 
alpha 10 (ITGA10), CD44, PTEN, cadherin-11, cadherin-12 
(CDH12), N-cadherin and E-cadherin have also been linked to 
EMT and associate with the expression of EMT transcriptionfac-
tors (15–21). Lactoferrin levels have been reported to be elevated 
in the cerebrospinal fluid of patients with CNS involvement of 
leukemia and lymphoma (22). In addition lactoferrin was of 
interest as it has been shown to downregulate the expression 
of intercellular adhesion molecule-1 (ICAM-1), this way possibly 
reducing the recruitment of leukocytes to the inflammatory site 
(23). In this work, we performed a screening of the above-men-
tioned molecules with an aim of finding possible biomarkers in 
order to identify patients with a high risk of CNS recurrence. The 
expression levels of these molecules were studied by means of 
immunohistochemistry (IHC) and immunoelectron microscopy 
(IEM). Gene-expression profiling (GEP) was performed to identify 




Patients included in the study were diagnosed and treated at the University 
Hospitals of Oulu, Jyväskylä, Kuopio and Tampere between 1997 and 2013. 
The median age of patients at diagnosis was 65 (range 27–82). The con-
trol group was selected from patients who did not have any signs of CNS 
disease during diagnosis, therapy or follow-up from the time of diagnosis 
until the end of the year 2015. Also the control group did not receive CNS 
prophylaxis. Patient information was collected from the hospital records, 
blinded from the laboratory results and used as encrypted data. Clinical 
data was collected from patients with primary systemic disease, includ-
ing GC/non-GC phenotype, age, lactate dehydrogenase, IPI and the num-
ber of extranodal lesions. Permission to use patient samples included in 
the study was granted by the Finnish National Supervisory Authority for 
Welfare and Health (6622/05.01.00.06/2010). This study was approved by 
the Ethics Committee of Oulu University Hospital (42/2010, 23.6.2010).
The study material for IHC consisted of diagnostic biopsy samples 
from 96 patients with newly diagnosed DLBCL, including 15 patients with 
PCNSLs, 31 with secondary CNS lymphomas (sCNSLs) and a control group 
of 50 patients with systemic DLBCLs (sDLBCL) that did not receive CNS 
prophylaxis. The sCNSL samples were diagnostic lymph node samples 
from primary diagnosis. IEM included two PCNSL samples, one sCNSL 
(brain biopsy), one sDLBCL and one reactive lymph node sample. GEP 
included two diagnostic lymph node fresh frozen tissue samples, one 
sDLBCL and one sCNSL sample from primary diagnosis.
Immunohistochemistry
Slide preparation was performed as described earlier except that before 
deparaffinization the slides were incubated overnight at +37°C (24). The 
antigen retrieval and the primary antibodies and their concentrations are 
presented in Supplementary Table  1, available at Carcinogenesis Online. 
Sample preparation continued as described in our previous study (9). To 
determine the germinal centre (GC) phenotype of each lymphoma sample, 
Hans’ algorithm was used with the same antibodies as in our previous 
study (9,25).
Immunoelectron microscopy
Tissue pieces were fixed in 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS) with 2.5% sucrose for 6 h at RT then immersed and 
stored in 2.3 M sucrose in PBS. Tissue pieces were placed on specimen 
stubs and frozen in liquid nitrogen. Ultrathin sections (70 nm) were cut 
with a Leica EM UC7 cryo-ultramicrotome. For immunolabelling, ultrathin 
sections were incubated in 0.1 % glycine + PBS followed by incubation in 
1% bovine serum albumin in PBS. All washes and antibody dilutions were 
performed in PBS + 1% bovine serum albumin. After incubation with the 
primary antibodies the sections were incubated with Protein A-gold con-
jugate (10 nm). Rabbit anti-mouse IgG (Jackson ImmunoResearch Europe 
Ltd, UK) was used as a secondary antibody. Sections were embedded in 
methylcellulose and examined in a Tecnai Spirit transmission electron 
microscope (FEI Company, Eindhoven, the Netherlands) equipped with a 
Quemesa digital camera (EMSIS GmbH, Münster, Germany). The antibod-
ies used were the same as for IHC.
Gene-expression profiling
The RNA isolation was performed using the RNeasy Mini Kit (Qiagen, USA) 
in accordance with the manufacturer’s instructions. A GeneChip protocol 
Abbreviations 
CNS  central nervous system
DLBCL  diffuse large B-cell lymphoma
EMT  epithelial–mesenchymal transition
GC  germinal centre
GEP  gene-expression profiling
IHC  immunohistochemistry
IEM  immunoelectron microscopy
PBS  phosphate-buffered saline
PCNSL  primary CNS lymphoma
PTEN  phosphatase and tensin homolog
sCNSL  secondary CNS lymphoma
sDLBCL  systemic DLBCL
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was used and the experimental procedures were performed in accordance 
with the Affymetrix GeneChip Expression Analysis Technical Manual. Using 
5 µg of total RNA as template, a double-stranded DNA was synthesized by 
means of the One-cycle cDNA synthesis kit (Affymetrix, USA) and T7-(dT)24 
primer. GeneChip Sample Cleanup Module (Qiagen, USA) was used to purify 
the DNA. By using an in vitro transcription (IVT) labelling kit (Affymetrix, 
USA) according to the manufacturer’s instructions, the IVT was performed 
to produce biotin labelled complementary RNA. Biotinylated complemen-
tary RNA was cleaned using the GeneChip Sample Cleanup Module (Qiagen), 
fragmented to 35–200 nucleotides, and hybridized to Affymetrix Human 
Genome U133 Plus 2.0 arrays that contain ~55 000 human transcripts. After 
washing, the array was stained with streptavidin–phycoerythrin (Molecular 
Probes). The staining signal was amplified by biotinylated anti-streptavidin 
(Vector Laboratories) followed by second staining with streptavidin-phyco-
erythrin, and then scanned on the GeneChip Scanner 3000.
Analysis
In the analysis of IHC staining, the location of positivity in the malig-
nant B-cells was determined separately in the nucleus, cytoplasm and/
or cell membrane. Then the percentage of positive cells was estimated 
separately for each location, from 0 to 100% with 5% accuracy. Micrographs 
from IHC staining patterns were obtained using an Olympus DP11 digital 
microscope camera (Olympus, Center Valley) and an Olympus BX41 micro-
scope. To import micrographs an HP Photo and Imaging software package 
(Hewlett-Packard Company, Palo Alto) was used.
The IEM samples were reviewed using a transmission electron micro-
scope. A general assessment was made of the expression pattern, taking 
into account the location (nucleus, cytoplasm and/or cell membrane) and 
the amount of positivity detected. Micrographs of each sample were taken 
using a Quemesa digital camera (EMSIS GmbH, Münster, Germany) and a 
Tecnai Spirit transmission electron microscope (FEI Company, Eindhoven, 
the Netherlands) as part of the analysis.
The expression data gained from GEP was analysed using dChip soft-
ware (26).
For statistical analysis, IBM SPSS Statistics for Windows 20.0 software 
(IBM Corp. Released 2011. Armonk, NY) was used. In order to analyse the 
associations between diagnosis (sDLBCL versus sCNSL) and the IHC pro-
tein expressions, the cut-off points for the latter were chosen using the 
receiver operating characteristic curve. The area under the curve (AUC) 
shows sensitivity versus 1-specificity. Only values greater than 0.5 were 
taken into account, values closer to 1.0 possessing a better discriminatory 
power. Due to the small study material, AUCs were relatively low. Cut-
off points were chosen by estimating a good balance between sensitivity 
and specificity. AUCs and cut-off points for proteins with statistically sig-
nificant associations with diagnosis are presented in the results section. 
Receiver operating characteristic curve-based cut-off points could not be 
chosen for all the proteins, due to the lack of discriminatory power. For 
the analysis of the associations between protein expressions and clinical 
parameters, median values were used as cut-off points for all the proteins, 
with these varying from 0.00 to 100.00.
IPI values were divided into two groups, with group one including 
patients with IPI points from 0 to 2, and group two including IPI points from 
3 to 5. The number of extranodal lesions was also divided into two groups, 
with group one including patients with zero or one extranodal lesions, and 
group two including patients with two or more extranodal lesions.
A Kruskal–Wallis test for continuous variables was performed includ-
ing all three different diagnoses (sDLBCL, sCNSL and PCNSL) and a Mann–
Whitney U test for two diagnostic groups (sCNSL and PCNSL). A chi-square 
test was used to determine the associations between protein expressions 
and clinical parameters as well as protein expressions and diagnosis 
(sDLBCL and sCNSL).
Results
Immunohistochemical expression in lymphoma 
samples
E-cadherin did not show any immunoreactivity. For ITGA10, 
CD44, PTEN, cadherin-11, N-cadherin, P-cadherin and lacto-
ferrin, cytoplasmic immunostaining was seen with all the 
antibodies used. Nuclear immunostaining was seen with all the 
antibodies used; except for CD44 there was no nuclear immuno-
reactivity. Membranous immunostaining was seen for ITGA10, 
CD44, PTEN and CDH12. The staining percentages are presented 
in Supplementary Table  2, available at Carcinogenesis Online. 
Figure 1 presents IHC staining patterns.
Immunoelectron microscpy expression in 
lymphoma samples
In PCNSL samples, the strongest expressions were seen for 
CD44, PTEN, cadherin-11 and N-cadherin. ITGA10 membranous 
expression was substantial in sCNSL. CD44 membranous and 
CDH12 nuclear expressions were substantial in sDLBCL. Strong 
nuclear expression of CDH12 was also detected in lymph node 
hyperplasia.
The proteins studied were also detected outside of lym-
phoma cells. Particularly lactoferrin was seen outside of lym-
phoma cells in all samples, most strongly in PCNSL. In sDLBCL 
and lymph node hyperplasia CDH12 was similarly expressed 
in normal lymphocytes as in lymphoma cells. CDH12 staining 
was also seen outside of lymphoma cells in PCNSL and sCNSL 
samples. In PCNSL, CD44 seemed to be expressed on the plasma 
membranes of the cells that came into contact with lymphoma 
cells with cell protrusions. PTEN was similarly expressed in 
PCNSL and sCNSL samples in cells that had long cell protrusions 
that came into contact with lymphoma cells. It was expressed in 
the membranes of these cells. The precise cell type could not be 
determined. Possibly these were antigen-presenting microglial 
cells. In PCNSL samples ITGA10 was also detected in cells that 
were not lymphoma cells. In addition it was seen in myelinated 
and non-myelinated neurons. Low expression of N-cadherin 
was detected in PCNSL in cells surrounding lymphoma cells. 
In sCNSL, the expression in surrounding cells was higher. High 
expression of cadherin-11 was seen in the plasma membranes 
of cells surrounding the lymphoma cells in the sCNSL sample. 
These cells could possibly represent antigen-presenting micro-
glial cells. Supplementary Figure  1, available at Carcinogenesis 
Online, presents electronmicroscopic expression in these cells.
Supplementary Table  3, available at Carcinogenesis Online, 
represents immunoelectron microscopy expression in all sam-
ples. Figure 2 presents electronmicroscopic expression.
Differences in gene-expression
The molecules studied were found in GEP data but only CD44, 
cadherin-11, lactoferrin and E-cadherin presented differences 
in the gene expression levels, being underexpressed in sCNSL 
compared to sDLBCL (Table 1).
Associations with central nervous system 
involvement
There were statistically significant differences between the 
expression of ITGA10, CD44, PTEN, cadherin-11 and lactoferrin 
stainings in different diagnostic groups. The differences gained 
from the Kruskal–Wallis test for continuous variables with all 
three diagnoses are presented here, mean and median values 
representing the staining percentages. Table  2 represents the 
differences gained from the Mann–Whitney U test comparing 
two diagnoses; sCNSL versus PCNSL and Table 3 the results of 
the chi-square test with chosen cut-off points (Tables 2 and 3).
ITGA10 cytoplasmic expression was lowest in sDLBCL (mean 
rank = 22.62, median = 0.00), higher in sCNSL (mean rank = 33.20, 
median  =  50.00) and highest in PCNSL (mean rank  =  46.85, 
median = 100.00) (P < 0.0005) (Figure 3A).
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ITGA 10 membranous expression was lowest in sDLBCL 
(mean rank  =  25.40, median 0.00), higher in PCNSL (mean 
rank  =  26.08, median  =  0.00) and highest in sCNSL (mean 
rank = 40.25, median = 100) (P = 0.002) (Figure 3B).
CD44 membranous expression was lowest in sCNSL 
(mean rank = 34.82, median = 50.00), higher in sDLBCL (mean 
rank  =  46.22, median  =  70.00) and highest in PCNSL (mean 
rank = 67.54, median = 100.00) (P = 0.001) (Figure 3D).
PTEN nuclear expression was lowest in sDLBCL (mean 
rank = 25.72, median = 0.00), higher in PCNSL (mean rank = 36.04, 
median  =  0.00) and highest in sCNSL (mean rank  =  38.37, 
median = 5.00) (P = 0.024) (Figure 3C).
Cadherin-11 nuclear expression was lowest in sCNSL 
(mean rank = 34.02, median = 30.00), higher in sDLBCL (mean 
rank  =  51.80, median  =  100.00) and highest in PCNSL (mean 
rank = 52.23, median = 100.00) (P = 0.006) (Figure 3E).
Cadherin-11 cytoplasmic expression was lowest in sCNSL 
(mean rank = 41.52, median 0.00), higher in sDLBCL (mean rank 
46.64, median = 0.00) and highest in PCNSL (mean rank = 54.00, 
median 0.00) (P  =  0.048). When comparing the expression 
between just two groups, sCNSL and sDLBCL, the result was 
non-significant.
Lactoferrin cytoplasmic expression was lowest in sDLBCL 
(mean rank  =  28.50, median  =  0.00), higher in sCNSL (mean 
rank  =  30.18, median  =  0.00) and highest in PCNSL (mean 
rank  =  52.85, median  =  100.00) (P  <  0.0005) (Figure  3F). When 
comparing the expression between just two groups, sCNSL and 
sDLBCL, the result was non-significant.
Associations with clinical parameters
CDH12 nuclear and ITGA10 membranous expressions had a 
positive association with the number of extranodal lesions 
Figure 1. Immunohistochemical staining patterns. (A) Positive cytoplasmic and membranous staining, with some faint nuclear staining, for ITGA10 in sCNSL sample, 
(B) positive nuclear and cytoplasmic staining for PTEN in PCNSL sample, (C) positive membranous staining for CD44 in PCNSL sample, (D) positive nuclear and cytoplas-
mic staining for cadherin-11 in sDLBCL sample, (E) positive nuclear and cytoplasmic staining for lactoferrin in PCNSL sample and (F) negative staining for E-cadherin 
in sDLBCL sample. Magnification ×20.
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(P = 0.026 and P = 0.006, respectively). CD44 membranous expres-
sion had an inverse association with the number of extranodal 
lesions (P = 0.037). CD12 nuclear, lactoferrin cytoplasmic, ITGA10 
cytoplasmic and ITGA membranous expressions had a positive 
association with the IPI score (P = 0.010, P = 0.029, P = 0.022 and 
P  =  0.007, respectively). PTEN nuclear expression had a posi-
tive association with lactate dehydrogenase (P = 0.002). Higher 
CD44 membranous expression was associated with the non-GC 
phenotype (P = 0.049). CD44 membranous expression also had a 
positive association with age over 60 (P = 0.034).
Discussion
In this work, we studied the biology of DLBCL’s CNS tropism with 
IHC, IEM and GEP with the aim of finding biological markers that 
would define DLBCL patients at high risk of CNS recurrence. We 
found that elevated levels of ITGA10 and PTEN were associated 
with CNS tropism, while CD44 and cadherin-11 expressions 
seemed to be protective of secondary CNS disease. Interestingly 
though, CD44, cadherin-11 and lactoferrin expressions were 
highest in PCNSL samples.
CNS recurrence occurs in about 5% of systemic DLBCL patients 
(2,3). It is a difficult complication with a very poor prognosis. 
Abramson et  al. conducted a retrospective study with results 
that were later confirmed in a prospective CRY study by Nordic 
Lymphoma Group, showing that CNS relapse risk can be reduced 
with high-dose methotrexate containing prophylactic chemo-
therapy (6,27). This conclusion was further supported by a retro-
spective study by Ferreri et  al (28). However, because high-dose 
methotrexate is a resource-demanding therapy with considera-
ble toxicity, it should be limited to patients with a high risk of CNS 
recurrence. Currently identification of these high-risk patients is 
performed based on clinical factors, which unfortunately have a 
poor specificity (8). Thus there is a need to define biological mark-
ers with a higher specificity for separating patients in need of 
CNS prophylactic treatment. Currently there are suggestions that 
double-hit genotype, non-GC phenotype, as well as CD5 positivity 
may have some prognostic relevance in this matter (29–31).
Understanding the pathophysiology of CNS lymphomas 
has been a challenge for years. An attractive hypothesis is that 
these malignant cells originate from extracranial sites but end 
up homing into the CNS due to highly selective CNS tropism. 
Results from recent studies have supported this hypothesis (32). 
In studies with GEP, differences in transcription of several pro-
teins have been observed when comparing normal lymphatic 
tissue and nodal or extranodal DLBCL with PCNSL. Our results 
are in line with these previous findings because it seems that 
adhesion-, migration- and ECM-related molecules play a pivotal 
role in CNS involvement of DLBCL (33,34).
In our previous study of CNS lymphomas, we assumed that 
CXCR4/CXCL12 and CXCR5/CXCL13 axis play an important role 
Figure 2. Micrographs representing electronmicroscopic expression patterns. (A) In the sCNSL sample ITGA10 molecules were localized to the cell membrane, (B) in 
the PCNSL sample PTEN molecules were mostly localized to the nucleus and cytoplasm, only few molecules seen on the cell membrane, (C) in the sDLBCL sample CD44 
molecules were mainly located to the cell membrane, with few molecules seen in the cytoplasm, (D) in the PCNSL sample cadherin-11 molecules were localizes to the 
nucleus and cytoplasm. In all of the images the cells are malignant lymphocytes. N  =  nucleus, C  =  cytoplasm, M  =  cell membrane, ↑ marks one of the molecules. 
Magnification ×46 000.











Negative fold-changes mark decreased expression in sCNSL compared to 
sDLBCL. The fold change for CD44 is a mean of five different values from five 
different probes. NC, no change.
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in CNS tropism of DLBCL (9). Concordantly Rubenstein et al. (35) 
have shown that CXCL12 and CXCL13 act as mediators of CNS 
lymphoma cell chemotaxis. In line with these findings, CXCR4/
CXCL12 signalling has been shown to induce EMT or an EMT-like 
process that enables cell migration towards the expression of 
chemokine ligands and invasive abilities (36–39). CXCR4/CXCL12 
signalling has also been shown to induce integrin and CD44 
activation and also CD44 localization to the leading edge during 
migration in human CD34+ stem/progenitor cells. These events 
together with integrin expression facilitate cell attachment to 
the extracellular space as well as the invasion and mobilization 
of cells (10,12). CD44 affects human haematopoietic progeni-
tor cell trafficking to the BM via interactions with hyaluronic 
acid (10). It is noteworthy that hyaluronic acid is also the main 
component of brain extracellular matrix (40). He et al. (41) found 
that perivascular tumour cells in PCNSL showed a strong CD44 
expression explaining the perivascular staining pattern. Our 
results are in line with this data describing the highest CD44 
expression in PCNSLs.
Our findings of integrin expression were in line with the 
hypothesis of cell migration, as ITGA10 showed a strong CNS 
tropism favouring function (42,43). The expression of membra-
nous ITGA10 had a positive association with two of the known 
clinical risk factors for CNS tropism: the number of extranodal 
lesions and higher IPI score.
PTEN is generally regarded as a tumour suppressor gene and 
in cancers its loss is associated with increased proliferation rate 
(44). Loss of PTEN expression has also been shown to occur in 
some B-cell lymphomas (45,46). We found its nuclear location 
to be associated with enhanced CNS tropism. In a work by Goh 
et al. nuclear trafficking of PTEN after an injury to the neurons 
was shown to lead to survival and thus to protect these cells 
from cell death, probably due to the depletion of PTEN from its 
functional place, the cytoplasm and cell membrane (47). Loss of 
PTEN has been shown to result in increased CXCR4 and CXCL12 
expression and invasion in prostate cancer cells (11). If nuclear 
localization is able to inhibit the cell cycle regulatory functions 
of PTEN, it could be that it can also lead to increased CXCR4 
expression as seen when PTEN expression is lost, and enhance 
the CNS tropism in this way. In our study nuclear PTEN was the 
only protein associated with increased lactate dehydrogenase 
levels.
Cadherin-11 cytoplasmic and nuclear expressions were 
highest in PCNSL, yet the latter was associated inversely with 
sCNSL. In contrast to this, in epithelial cancers, cadherin-11 is 
often associated with mesenchymal features gained through 
EMT (17).
In our results, lactoferrin expression was highest in PCNSL 
and second highest in sCNSL when studied with IHC and IEM. 
When comparing sDLBCL and sCNSL, no statistically significant 
differences were seen. In GEP, higher expression level was seen 
in sDLBCL samples but GEP did not include PCNSL samples that 
had the most abundant expression in IHC and IEM. Lactoferrin 
has been shown to be produced in the CNS by activated micro-
glial cells and its expression has been associated with neuro-
logical disorders affecting the CNS, such as Alzheimer’s and 
Parkinson’s diseases. It seems that lactoferrin expression is 
upregulated as a consequence of inflammatory conditions and 
under oxidative stress (48). Most likely this could also be the 
case in PCNSL.
Taken together, our findings support the hypothesis that 
CXCR4 signalling might participate in the initiation of lym-
phoma cells homing into the CNS. This again may enable the 
morphological and expressional changes seen in this study. In a 
work by Ricciardi et al. (49) mesenchymal stromal cell-like fea-
tures gained through EMT conferred cancer cells with immune-
modulatory properties which again possibly attenuate cancer 
cell immune escape and progression.
When the IHC, IEM and GEP results were compared they 
were mostly in concordance with each other. All of the mole-
cules studied were found in GEP and four presented with gene-
expressional changes. The expressional changes were similar 
to IHC and IEM results, except that E-cadherin was not seen 
to be expressed at a protein level. Lactoferrin expression also 
presented with minor differences. The small number of GEP 
samples used in this study limits the reliability of the results. 
However, concordant results seen in larger IHC and IEM materi-
als indicate that these findings seem to present a relevant event 
Table 3. Cut-off points and associations of protein IHC expressions and secondary CNS disease
Protein, location AUC CI Cut-off Association P value
CD44, M 0.668 0.514–0.821 70.00 ↓ 0.015
PTEN, N 0.694 0.547–0.840 0.00 ↑ 0.011
ITGA10, N 0.657 0.500–0.815 10.00 ↓ 0.044
ITGA10, C 0.679 0.519–0.838 10.00 ↑ 0.002
ITGA10, M 0.745 0.606–0.884 0.00 ↑ 0.007
Cadherin-11, N 0.673 0.514–0.831 70.00 ↓ <0.001
Diagnoses studied, sDLBCL and sCNSL. AUC, area under curve; CI, confidence interval; C, cytoplasm; M, membrane; N, nucleus. Cut-off signifies the chosen cut-off 
point. ↓ = inverse association and ↑ = positive association with CNS involvement.
Table 2. Associations of protein immunohistochemical expressions and diagnosis (sCNSL and PCNSL)
Protein, location Mean rank, sCNSL
Median
sCNSL Mean rank, PCNSL
Median
PCNSL P value
CD44, M 18.12 50 30.96 100 0.002
Lactoferrin, C 18.00 0 33.23 100 <0.001
P cadherin, N 19.84 5 28.85 20 0.030
ITGA10, C 18.70 50 29.62 100 0.006
ITGA10, M 24.73 100 15.69 0 0.014
C, cytoplasm; M, membrane; N,nucleus.
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in DLBCL CNS tropism. The few discrepancies may be explained 
by the methods used; IHC measures the expression of the stud-
ied proteins within a sample tissue whereas GEP measures 
the expression of specific messenger RNAs in the sample. IHC 
and IEM results were also mostly in concordance with each 
other, with only a couple of differences. IHC results represent 
Figure 3. Associations of protein immunohistochemical expressions and diagnoses. A Kruskal–Wallis test was used to determine the associations between protein 
expression and different diagnoses for (A) ITGA10 cytoplasmic expression (P < 0.0005), (B) ITGA10 membranous expression (P = 0.002), (C) PTEN nuclear expression 
(P = 0.024), (D) CD44 membranous expression (P = 0.001), (E) cadherin-11 nuclear expression (P = 0.006) and (F) lactoferrin cytoplasmic expression (P < 0.0005). The boxes 
represent the interquartile range, the whiskers represent the 10th and 90th percentiles and the highlighted lines across the boxes indicate the median values. Circles 
represent extremes and asterisks represent outliers. 
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a collection of multiple samples and a large number of cells are 
evaluated. IEM expression on the other hand represents one or 
two samples, and from those a single cell per view. This might 
cause a selection bias if the expression in this specific sample is 
below average. Using light microscopy, it is harder to tell cyto-
plasmic and membranous staining apart than it is in electron 
microscopy. This might represent another bias to the results.
Our findings imply that some biological events are com-
mon in both primary and secondary CNS lymphomas. Yet the 
fact that PCNSL samples are brain biopsies and sCNSL sam-
ples from lymph nodes from a time of the primary diagnosis, 
the differences in the microenvironment might also lead to the 
seemingly different results observed between these two groups, 
and this impact could not be excluded in this study. In addition, 
PCNSL and sCNSL are two different entities and there might also 
be differences due to this.
In this work, we have shown that lymphoma CNS tropism 
is linked to enhanced expression of integrins (ITGA10 in this 
study) and PTEN, when again sCNSL is linked to decreased CD44 
and cadherin-11 expressions. In PCNSL, lactoferrin seems to be 
upregulated. This data is in line with current knowledge of mor-
phological and protein expressional changes occurring during 
cell migration and invasion, and with the current GEP data of 
CNS lymphomas where differences in the expression of adhe-
sion and ECM-related genes have been seen (33,34). These EMT-
like changes seen in our study might also attenuate lymphoma 
cell immune escape (49). To our knowledge, this is the first 
study exploring the role of ITGA10, CD44, PTEN, cadherin-11, 
CDH12, N-cadherin, P-cadherin, lactoferrin and E-cadherin in 
DLBCLs and especially in CNS lymphomas. The present study 
was a retrospective one and the size was too small to calculate 
the positive and negative prognostic values of these markers as 
well as to perform multivariate analyses comparing independ-
ent values of these markers with clinical factors. Currently the 
most powerful markers for prediction of CNS tropism seem to 
be non-GC phenotype, double-hit genotype and CD5 positiv-
ity (28–31). From our candidate markers, only CD44 expres-
sion was associated with non-GC phenotype, implying that the 
rest of the proteins studied may give new prognostic value for 
CNS relapse prediction in both GC and non-GC phenotypes. 
Unfortunately translocation data was not available from our 
cases. However the findings are able to support a hypothesis 
that cytoplasmic and membranous ITGA10, nuclear PTEN and 
membranous CD44 expressions should be studied as promis-
ing candidates to be used as biological markers for screening 
of systemic DLBCL patients at elevated CNS relapse risk. These 
results are highly preliminary and need to be validated in a 
larger prospective trial.
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